<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697032</url>
  </required_header>
  <id_info>
    <org_study_id>NL2015.0704</org_study_id>
    <nct_id>NCT02697032</nct_id>
  </id_info>
  <brief_title>FDHT PET and Bicalutamide in Metastatic Breast Cancer</brief_title>
  <official_title>FDHT-PET to Visualize the Effect on the Androgen Receptor Level by Bicalutamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The purpose is to evaluate whether non-invasive in vivo imaging of androgen&#xD;
      receptor (AR) presence in metastatic breast cancer patients by means of&#xD;
      18F-fluoro-dihydrotestosterone positron emission tomography (FDHT-PET) can be used to predict&#xD;
      (early) treatment response to, and optimal dosing of, the anti androgen bicalutamide. The&#xD;
      ultimate goal is to contribute to optimal selection of breast cancer patients for anti&#xD;
      androgen treatment. Objective: Feasibility to detect a diffrence in uptake on 18F-FDHT scan&#xD;
      after 6 weeks of treatment with bicalutamide in metastatic breast cancer patients. Secondary&#xD;
      Objectives: to describe whether changes in 18F-FDHT tracer uptake after six weeks associates&#xD;
      with response to bicalutamide, to describe whether changes in AR availability are different&#xD;
      for breast cancer subgroups during treatment with bicalutamide and to describe whether&#xD;
      18F-FDHT tracer uptake is influenced by the amount of AR tumor expression. Study design: This&#xD;
      is a single arm, one stage feasibility study, which will be executed in the University&#xD;
      Medical Center Groningen, The Netherlands. The primary endpoint of the study is to evaluate&#xD;
      the difference in 18F-FDHT uptake in tumor lesions after 6 weeks of bicalutamide treatment in&#xD;
      patients with AR-positive metastatic breast cancer. Patients will be treated with&#xD;
      bicalutamide until progression or unacceptable toxicity is encountered. Study population: The&#xD;
      investigators will include 20 postmenopausal metastatic breast cancer patients with an AR&#xD;
      positive, HER2 negative tumor. Patients should be restaged clinically with bone scintigraphy&#xD;
      and CT scan within a 6 week timeframe of the PET examinations. Intervention: All patients&#xD;
      will receive a baseline FDHT-PET scan and start with bicalutamide treatment 150mg daily.&#xD;
      During follow-up patients will receive one FDHT-PET scan after 6 weeks. Treatment with&#xD;
      bicalutamide will continue until progression or unacceptable toxicity is encountered. Main&#xD;
      study endpoint: The percent difference in 18F-FDHT uptake in tumor lesions after 6 weeks of&#xD;
      monotherapy bicalutamide. A minimum decrease of 20% in 18F-FDHT uptake after 6 weeks compared&#xD;
      to baseline uptake with an α of 0.05 and a power of 80%, is considered clinical significant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">November 25, 2019</completion_date>
  <primary_completion_date type="Actual">November 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quantify residual AR binding sites in metastatic breast cancer</measure>
    <time_frame>6 weeks</time_frame>
    <description>To quantify residual AR binding sites in metastatic breast cancer after 6 weeks of treatment with bicalutamide.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine whether changes in 18F-FDHT uptake</measure>
    <time_frame>6 weeks</time_frame>
    <description>To determine whether changes in 18F-FDHT uptake after 6 weeks associates with response to bicalutamide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence amount of AR tumor expression</measure>
    <time_frame>6 weeks</time_frame>
    <description>To determine whether 18F-FDHT tracer uptake is influenced by the amount of AR tumor expression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in AR availability</measure>
    <time_frame>6 weeks</time_frame>
    <description>To determine whether changes in AR availability are different for breast cancer subgroups during treatment with bicalutamide</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At day 0 before start with bicalutamide, a FDHT-PET/CT will be performed, and one after 6 weeks (i.e. 2 weeks after steady-state). The second FDHT-PET will be performed to determine if this scan can be used as a biomarker for early response. Patients will be treated with bicalutamide until progression or unacceptable toxicity is encountered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>150mg</description>
    <arm_group_label>Patients</arm_group_label>
    <other_name>casodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FDHT PET</intervention_name>
    <description>PET scan</description>
    <arm_group_label>Patients</arm_group_label>
    <other_name>18F-FDHT PET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A history of histological proven AR-positive (i.e. &gt;10% staining), HER2-negative&#xD;
             metastatic breast cancer (preferably assessment on fresh metastasis biopsy,&#xD;
             alternatively archival metastasis biopsy)&#xD;
&#xD;
          2. Tumor progression after at least one line of systemic treatment&#xD;
&#xD;
          3. Measurable disease according to RECIST 1.1; or evaluable disease&#xD;
&#xD;
          4. Age ≥ 18 years&#xD;
&#xD;
          5. Postmenopausal status defined as one of the following:&#xD;
&#xD;
               -  Age ≥60 years&#xD;
&#xD;
               -  Previous bilateral oophorectomy&#xD;
&#xD;
               -  Age &lt;60 years and amenorrhea for &gt;12 months in the absence of interfering&#xD;
                  hormonal therapies (such as LH-RH agonists and ER-antagonists&#xD;
&#xD;
               -  Age &lt;60 years using ER antagonists should have amenorrhea for &gt;12 months and FSH&#xD;
                  &gt;24U/L and LH&gt;14U/L&#xD;
&#xD;
          6. Adequate hematological, renal and liver function as follows:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count &gt;100 x 109/L&#xD;
&#xD;
               -  White blood cell count &gt;3 x 109/L&#xD;
&#xD;
               -  AST and ALT &lt;3.0 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Alkaline phosphatase &lt;2.5 x ULN&#xD;
&#xD;
               -  Creatinine clearance &gt;50mL/min&#xD;
&#xD;
               -  Lipase/amylase &lt;1/5 x ULN&#xD;
&#xD;
               -  Protrombin time, partial tromboplastin time and INR &lt;1.5 x ULN&#xD;
&#xD;
          7. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to comply with the protocol&#xD;
&#xD;
          2. Evidence of central nervous metastases&#xD;
&#xD;
          3. Presence of life-threatening visceral metastases&#xD;
&#xD;
          4. Corrected QT interval (QTc) &gt;500millliseconds at screening&#xD;
&#xD;
          5. Recent history of cardiac disease, including myocardial infarction, unstable angina&#xD;
             pectoris or uncontrolled arrhythmia within 6 months prior to screening; or evidence of&#xD;
             severe congestive heart failure with New York Heart Association severity&#xD;
             classification &gt; class I.&#xD;
&#xD;
          6. Recent history of trombo-embolic events within 6 months prior to screening&#xD;
&#xD;
          7. Hepatic impairment (Child-Pugh Class B or C)&#xD;
&#xD;
          8. Severe concurrent disease, infection, co morbid condition that, in the judgment of the&#xD;
             investigator would make the patient inappropriate for enrollment&#xD;
&#xD;
          9. The concomitant use of strong CYP3A4 inhibitors (see table 1)&#xD;
&#xD;
         10. Previous anti-androgen treatment&#xD;
&#xD;
         11. Concurrent use of ER-directed anti hormonal therapies&#xD;
&#xD;
         12. Radiotherapy or major surgery within 4 weeks before baseline PET scanning&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolien P. Schröder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 25, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>C.P. Schroder</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>FDHT</keyword>
  <keyword>PET</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Bicalutamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

